La Jolla, California -- Biotechnology company DermTech has secured part of a new venture capital equity financing round, according to an SEC regulatory filing.
DermTech has commercialized a qPCR assay for skin samples collected using adhesive tape biopsy methods, instead of more invasive biopsies.
The company's technology can then analyze a variety of gene targets to assess their level of RNA expression.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
DermTech is still seeking $19.23 million in additional financing, according to the filing.